Ivermectin for COVID-19 : promising but not yet conclusive
CITATION: Van Rensburg, R. et al. 2021. Ivermectin for COVID-19 : promising but not yet conclusive. South African Medical Journal, 111(3):188, doi:10.7196/SAMJ.2021.v111i3.15522.
The original publication is available at http://www.samj.org.za
Ivermectin has been proposed as a potential definitive and prophylactic treatment for COVID-19. Ivermectin is an anthelmintic drug that is usually indicated for filarial and resistant scabies infections, but has been shown to have antiviral activity and anti-inflammatory activity in vitro.[2,3] Ivermectin has the potential to be a promising directed therapy in the drug armamentarium against COVID-19, as it has been shown to have in vitro activity against SARS-CoV-2. Several randomised controlled trials (RCTs) and observational studies have reported on the effectiveness and safety outcomes of ivermectin in COVID-19.[1,5] These data are very promising, showing large treatment effects and acceptable adverse effect profiles for ivermectin against COVID-19, especially when combined in metaanalyses.